Design of novel peptide ligands which have opioid agonist activity and CCK antagonist activity for the treatment of pain.
Disease states such as neuropathic pain offer special challenges in drug design due to the system changes which accompany these diseases. In this manuscript we provide an example of a new approach to drug design in which we have modified a potent and selective peptide ligand for the CCK-2 receptor to a peptide which has potent agonist binding affinity and bioactivity at delta and mu opioid receptors, and simultaneous antagonist activity at CCK receptors. De novo design based on the concept of overlapping pharmacophores was a central hypothesis of this design, and led to compounds such as H-Tyr-DPhe-Gly-DTrp-NMeNle-Asp-Phe-NH(2) (i.e., RSA 601) which have the designed properties.
Hruby
V J
VJ
Department of Chemistry, University of Arizona, Tucson 85721, USA. hruby@u.arizona.edu
Agnes
R S
RS
Davis
P
P
Ma
S-W
SW
Lee
Y S
YS
Vanderah
T W
TW
Lai
J
J
Porreca
F
F
D000818:Animals; D001665:Binding Sites; D015195:Drug Design; D006168:Guinea Pigs; D007082:Ileum / Q000187:drug effects / Q000378:metabolism; D008024:Ligands; D008297:Male; D051379:Mice; D009842:Oligopeptides / Q000737:chemistry / Q000494:pharmacology*; D010146:Pain / Q000188:drug therapy* / Q000378:metabolism; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors*; D011957:Receptors, Opioid / Q000819:agonists*; D017465:Receptors, Opioid, delta / Q000819:agonists; D017450:Receptors, Opioid, mu / Q000819:agonists; D013329:Structure-Activity Relationship; D014649:Vas Deferens / Q000187:drug effects / Q000378:metabolism
D008024:Ligands; D009842:Oligopeptides; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin; D011957:Receptors, Opioid; D017465:Receptors, Opioid, delta; D017450:Receptors, Opioid, mu; C571449:tyrosyl-phenylalanyl-glycyl-tryptophyl-N-methylnorleucyl-aspartyl-phenylalaninamide